OPEN ACCESS Freely available online

Journal of Hepatology and Gastrointestinal disorders

Opinion Article

Pharmacologic and Non-Pharmacologic Strategies in the Management of Hepatic Encephalopathy: A Holistic Approach

Catherine L. Hayes*

Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

DESCRIPTION

Hepatic Encephalopathy (HE) remains one of the most complex and debilitating complications of cirrhosis. It not only reduces quality of life for patients but also places significant economic strain on healthcare systems through recurrent hospitalizations. Despite decades of research, the management of HE continues to present clinical challenges, largely due to its multifactorial pathophysiology, episodic nature and the social vulnerabilities of the affected population. In high-income countries, we are fortunate to have access to a variety of pharmacologic and non-pharmacologic strategies, yet the coordination and application of these tools often fall short of their potential.

Pharmacologic management of HE has traditionally centered around lactulose, a non-absorbable disaccharide that lowers intestinal ammonia by acidifying the colon and accelerating transit. It remains the first-line therapy for both overt and covert HE. While its efficacy is well-supported, adherence is frequently limited by its gastrointestinal side effects, including bloating, diarrhoea and cramping. In clinical practice, we have encountered many patients who either reduce their lactulose dose independently or discontinue it altogether due to poor tolerance, resulting in preventable hospital admissions. Rifaximin, a poorly absorbed antibiotic that alters gut flora and reduces ammonia production, is an essential adjunctive agent. Studies have demonstrated its effectiveness in reducing HE recurrence and hospitalizations, particularly when added to lactulose therapy. The major limitation of rifaximin, however, remains its cost. Even in high-income countries, insurance coverage varies and out-of-pocket expenses can be prohibitive for some patients. This reflects a broader issue in hepatology access to essential supportive therapies is not guaranteed, even in well-resourced systems.

Other agents, such as L-Ornithine L-Aspartate (LOLA) and Branched-Chain Amino Acids (BCAAs), have shown promise in select populations but are not widely adopted in routine clinical care, partly due to cost, availability and limited long-term data. There is also growing interest in Fecal Microbiota Transplantation (FMT) and targeted microbiome interventions, which have shown early promise in improving cognitive function and reducing inflammation. However, these are still considered investigational and are not yet available in standard clinical settings. What is increasingly clear is that pharmacologic therapy alone is insufficient. Non-pharmacologic strategies must be equally emphasized, particularly in the outpatient setting. Nutritional support is paramount. The outdated dogma of protein restriction has been firmly debunked; instead, patients should be encouraged to consume 1.2-1.5 g/kg/day of protein, with an emphasis on plant-based and dairy sources. Late evening snacks rich in complex carbohydrates have also been shown to reduce catabolism and improve nitrogen balance. Despite these guidelines, many patients remain undernourished due to poor appetite, socioeconomic constraints, or persistent myths about diet in liver disease.

Education and caregiver involvement are also crucial. HE often impairs insight and memory, making self-management difficult. In high-income countries, where interdisciplinary teams are more readily available, integrating clinical pharmacists, dietitians, social workers and nurse educators into HE management should be the norm, not the exception. Unfortunately, many clinics operate in silos and patients are left to navigate complex medication regimens and dietary recommendations on their own. Another key area of non-pharmacologic intervention is prevention of precipitating factors. Constipation, dehydration, gastrointestinal bleeding, infections and sedative use are well-known triggers. Ensuring that patients have access to clean water, regular follow-up and safe medication reviews can dramatically reduce episodes of HE. In our clinic, we have implemented a pharmacist-led medication reconciliation program and seen notable reductions in unnecessary sedative use.

Cognitive rehabilitation is an underutilized but potentially transformative intervention. Even after resolution of overt HE, many patients experience residual cognitive deficits that impact their ability to work or live independently. Pilot programs using memory training, executive function exercises and digital cognitive tools are beginning to show promise. While these interventions are still evolving, they represent a critical step

Correspondence to: Catherine L. Hayes, Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada, E-mail: catherinehaes@mtsinai.utoronto.ca

Received: 02-Mar -2025, Manuscript No. JHGD-25-38262; **Editor assigned:** 04-Mar-2025, PreQC No. JHGD-25-38262 (PQ); **Reviewed:** 18-Mar-2025, QC No. JHGD-25-38262; **Revised:** 25-Mar-2025, Manuscript No. JHGD-25-38262 (R); **Published:** 03-Apr-2025, DOI: 10.35248/2475-3181.25.11.353.

Citation: Hayes CL (2025). Pharmacologic and Non-Pharmacologic Strategies in the Management of Hepatic Encephalopathy: A Holistic Approach. J Hepatol Gastroint Dis.11:353.

toward restoring functional independence. In terms of systems-level care, telehealth and digital monitoring tools offer new opportunities for remote HE management. Mobile apps that track bowel movements, lactulose adherence and symptom severity can help patients and clinicians detect early signs of decompensation. In high-income countries, where digital infrastructure is widespread, these tools should be further integrated into routine liver care.

CONCLUSION

Hepatic encephalopathy is a multifaceted condition that demands a multifaceted response. While pharmacologic therapies such as lactulose and rifaximin remain cornerstones, the real opportunity lies in integrating these treatments with robust non-pharmacologic strategies. Nutritional optimization, caregiver education, prevention of precipitants and cognitive rehabilitation must become standard components of care. In high-income countries, where resources are abundant, the challenge is not a lack of tools, but a lack of coordination. We must adopt a holistic, team-based approach to HE management that prioritizes the patient's overall well-being, not just their ammonia levels. Only then can we reduce the burden of this debilitating condition and offer patients a chance at meaningful recovery.